Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. 2763602-16-8
2. Icotrokinra [inn]
3. Muw8fp7hnz
4. Schembl23656544
5. Ex-a9714
6. Hy-p10587
7. Glycinamide, N-acetyl-3-mercapto-l-valyl-l-asparaginyl-l-threonyl-7-methyl-l-tryptophyl-n6-acetyl-l-lysyl-3-mercapto-l-valyl-o-(2-aminoethyl)-l-tyrosyl-3-(2-naphthalenyl)-l-alanyl-4-aminotetrahydro-2h-pyran-4-carbonyl-l-alpha-glutamyl-l-asparaginyl-3-(3-pyridinyl)-l-alanyl-n2-methyl-, Cyclic (1-->6)-disulfide
| Molecular Weight | 1898.2 g/mol |
|---|---|
| Molecular Formula | C90H120N20O22S2 |
| XLogP3 | -3.4 |
| Hydrogen Bond Donor Count | 20 |
| Hydrogen Bond Acceptor Count | 26 |
| Rotatable Bond Count | 40 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 709 |
| Heavy Atom Count | 134 |
| Formal Charge | 0 |
| Complexity | 4100 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 12 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
API SUPPLIERS
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
Details:
JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Lead Product(s): Icotrokinra
Therapeutic Area: Dermatology Brand Name: JNJ-2113
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 09, 2025
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Icotrokinra Clears Skin in Tough Scalp and Genital Psoriasis Patients
Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Product Name : JNJ-2113
Product Type : Peptide
Upfront Cash : Inapplicable
May 09, 2025
Details:
JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Lead Product(s): Icotrokinra
Therapeutic Area: Dermatology Brand Name: JNJ-2113
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2025
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Icotrokinra Clears Plaque Psoriasis in 75% Of Teens in Daily Pill Trial
Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Product Name : JNJ-2113
Product Type : Peptide
Upfront Cash : Inapplicable
April 10, 2025
Details:
JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied for the treatment of moderate-to-severe ulcerative colitis.
Lead Product(s): Icotrokinra
Therapeutic Area: Immunology Brand Name: JNJ-2113
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2025
Lead Product(s) : Icotrokinra
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Icotrokinra Meets Primary Endpoint in Ulcerative Colitis Study
Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied for the treatment of moderate-to-severe ulcerative colitis.
Product Name : JNJ-2113
Product Type : Peptide
Upfront Cash : Inapplicable
March 10, 2025
Details:
JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Lead Product(s): Icotrokinra
Therapeutic Area: Dermatology Brand Name: JNJ-2113
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 08, 2025
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Icotrokinra Study Results Suggest Potential to Redefine Treatment Standards in Psoriasis
Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Product Name : JNJ-2113
Product Type : Peptide
Upfront Cash : Inapplicable
March 08, 2025
Details:
JNJ-2113 (icotrokinra) is a first and only targeted oral peptide that is designed to selectively block the IL-23R. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Lead Product(s): Icotrokinra
Therapeutic Area: Dermatology Brand Name: JNJ-2113
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Protagonist Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2024
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Protagonist Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Protagonist Announces Positive Results for Icotrokinra in Phase 3 Plaque Psoriasis
Details : JNJ-2113 (icotrokinra) is a first and only targeted oral peptide that is designed to selectively block the IL-23R. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Product Name : JNJ-2113
Product Type : Peptide
Upfront Cash : Inapplicable
November 18, 2024
Details:
JNJ-2113 is a first and only targeted oral peptide that is designed to selectively block the IL-23 receptor. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Lead Product(s): Icotrokinra
Therapeutic Area: Dermatology Brand Name: JNJ-2113
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 03, 2024
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Data Shows JNJ-2113 Maintained Skin Clearance in Moderate-To-Severe Psoriasis
Details : JNJ-2113 is a first and only targeted oral peptide that is designed to selectively block the IL-23 receptor. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Product Name : JNJ-2113
Product Type : Peptide
Upfront Cash : Inapplicable
September 03, 2024
Details:
Under the Agreement, Janssen is conducting Phase 2b trial of JNJ-2113 (formerly known as PN-235), a first-in-class targeted oral peptide designed to selectively block the IL-23 receptor, in moderately to severely active ulcerative colitis.
Lead Product(s): Icotrokinra
Therapeutic Area: Immunology Brand Name: JNJ-2113
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Janssen Biotech
Deal Size: $987.5 million Upfront Cash: $50.0 million
Deal Type: Licensing Agreement December 13, 2023
Lead Product(s) : Icotrokinra
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Janssen Biotech
Deal Size : $987.5 million
Deal Type : Licensing Agreement
Details : Under the Agreement, Janssen is conducting Phase 2b trial of JNJ-2113 (formerly known as PN-235), a first-in-class targeted oral peptide designed to selectively block the IL-23 receptor, in moderately to severely active ulcerative colitis.
Product Name : JNJ-2113
Product Type : Peptide
Upfront Cash : $50.0 million
December 13, 2023
Details:
JNJ-2113 is a first and only targeted oral peptide that is designed to selectively block the IL-23 receptor. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Lead Product(s): Icotrokinra
Therapeutic Area: Dermatology Brand Name: JNJ-2113
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Protagonist Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 27, 2023
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Protagonist Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JNJ-2113 is a first and only targeted oral peptide that is designed to selectively block the IL-23 receptor. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Product Name : JNJ-2113
Product Type : Peptide
Upfront Cash : Inapplicable
November 27, 2023
Details:
JNJ-2113 (formerly known as PN-235) is the first-and only-in-class oral IL-23 receptor antagonist as a potential oral targeted therapy for plaque psoriasis.
Lead Product(s): Icotrokinra
Therapeutic Area: Dermatology Brand Name: JNJ-2113
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Johnson & Johnson Innovative Medicine
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 03, 2023
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JNJ-2113 (formerly known as PN-235) is the first-and only-in-class oral IL-23 receptor antagonist as a potential oral targeted therapy for plaque psoriasis.
Product Name : JNJ-2113
Product Type : Peptide
Upfront Cash : Inapplicable
July 03, 2023
Details:
JNJ-2113 (formerly known as PN-235) is the first-and only-in-class oral IL-23 receptor antagonist as a potential oral targeted therapy for plaque psoriasis.
Lead Product(s): Icotrokinra
Therapeutic Area: Dermatology Brand Name: JNJ-2113
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Protagonist Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 07, 2023
Lead Product(s) : Icotrokinra
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Protagonist Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JNJ-2113 (formerly known as PN-235) is the first-and only-in-class oral IL-23 receptor antagonist as a potential oral targeted therapy for plaque psoriasis.
Product Name : JNJ-2113
Product Type : Peptide
Upfront Cash : Inapplicable
April 07, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
ABOUT THIS PAGE
